The Effect of Natural Molecules on HPV Infection

The purpose of the study is to evaluate the effect of the administration of natural molecules in the treatment of HPV infection.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HPV (Human Papillomavirus)-Associated Communicable Diseases DNA Virus Infections Disease Attributes Genital Diseases Infections Papillomavirus Infections Pathologic Processes Pathological Conditions, Signs and Symptoms Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Tumor Virus Infections Urogenital Diseases Virus Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Agunco

Rome, Italy

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

HPV DNA test positivity
over 18 years

Exclusion criteria

pregnancy
breastfeeding
assumption of other products containing EGCG or green tea
primary immunodepression or pharmacological induced one

Treatment and study plan

EGCG, FA, HA, B12

Dietary Supplement

EGCG + FA + HA + B12 (1 cps /die)

Primary outcomes

HPV DNA test negativity

Time frame: 6 months of treatment

Percentage

Sponsors and collaborators

Lead sponsor

AGUNCO Obstetrics and Gynecology Centre

Other

Registry information

Official study title

Counteracting HPV Infection with Natural Molecules

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Oct 28, 2024
Registry last updated: Mar 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed